1. US Food and Drug Administration (2009) NDA approvals by therapeutic potential and chemical type. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAApprovalsbyTherapeuticPotentialandChemicalType/default.htm . Accessed 14 December 2011
2. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185
3. Berenson A (14 November 2005) Big drug makers see sales decline with their image. New York Times. Available from URL: http://www.nytimes.com/2005/11/14/business/14pharma.html
4. Hollis A (13 December 2004) Me-too drugs: is there a problem? Submission to the WHO Commission on Intellectual Property and Public Health. Available from URL: http://www.who.int/intellectualproperty/topics/ip/Me-tooDrugs_Hollis1.pdf
5. US Congress Office of Technology Assessment (1993) Pharmaceutical R&D: costs, risks and rewards. Available from URL: http://www.fas.org/ota/reports/9336.pdf